MaxCyte (NASDAQ:MXCT – Get Rating) and Bitcoin Group (OTCMKTS:BTGGF – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.
Volatility and Risk
MaxCyte has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Bitcoin Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.
Valuation & Earnings
This table compares MaxCyte and Bitcoin Group’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $44.26 million | 11.64 | -$23.57 million | ($0.30) | -16.67 |
| Bitcoin Group | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares MaxCyte and Bitcoin Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -73.66% | -11.99% | -10.62% |
| Bitcoin Group | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent ratings for MaxCyte and Bitcoin Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 0 | 0 | 2 | 0 | 3.00 |
| Bitcoin Group | 0 | 0 | 0 | 0 | N/A |
MaxCyte presently has a consensus target price of $10.50, indicating a potential upside of 110.00%. Given MaxCyte’s higher possible upside, research analysts plainly believe MaxCyte is more favorable than Bitcoin Group.
Insider & Institutional Ownership
66.7% of MaxCyte shares are held by institutional investors. 6.0% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
MaxCyte beats Bitcoin Group on 6 of the 9 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Bitcoin Group
Bitcoin Group SE, a private equity and consulting company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
